Identity
GHRP-2 is an experimental growth-hormone secretagogue receptor agonist.
Selected study only; not a complete clinical review.
Peptide library
GHRP-2
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
Seven men in an acute infusion experiment provide physiological evidence about appetite and GH. That design cannot establish sustained recovery, muscle gain or long-term metabolic safety.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
Seven lean healthy men; acute controlled infusion experiment.
What the sources found
Subcutaneous infusion increased food intake and growth-hormone secretion; these measures do not establish lasting muscle or recovery benefits.
Regulatory scope
Current authorization for the exact product and jurisdiction was not independently checked in this snapshot. A clinical trial is not marketing authorization.
What remains unknown
Selected indexed primary-study abstract reviewed. Full methods, bias, all safety outcomes, product stability, current jurisdictional authorization and a comprehensive literature search remain outstanding. This is not a complete clinical review.
How it works
GHRP-2 is an experimental growth-hormone secretagogue receptor agonist.
The study-specific findings below distinguish biological activity from demonstrated treatment benefit.
Limited clinical evidence
The catalog describes a limited clinical evidence base. Small or uncontrolled studies may not separate treatment effects from chance, placebo effects or bias.
Reported adverse effects
- The small acute experiment cannot define chronic endocrine or metabolic risks.
Selected study only; not a complete clinical review.
Contraindications
- A complete contraindication and interaction review remains outstanding.
Limited clinical evidence
The catalog describes a limited clinical evidence base. Small or uncontrolled studies may not separate treatment effects from chance, placebo effects or bias.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
Subcutaneous infusion increased food intake and growth-hormone secretion; these measures do not establish lasting muscle or recovery benefits.
Selected study only; not a complete clinical review.
Adverseeffects
The small acute experiment cannot define chronic endocrine or metabolic risks.
Selected study only; not a complete clinical review.
References
Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. 2005.
PMID: 15699539
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.